Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Boehringer Ingelheim’s commitment towards a healthier and more sustainable future is firmly anchored in our corporate philosophy since its founding and translated through the Sustainable Development for Generations framework.
Therefore, sustainability is a very important topic in our R&D organization, the Innovation Unit (IU). In the Global IU, we want to improve the environmental footprint of our future medicines by integrating criteria for sustainability into the design of our products during their R&D lifecycle.
To support this effort and to make a difference, we want to collaborate with the best scientific experts under sponsorship of our IUMore Green Grant program. To be inclusive and cover all regions globally, we will share important research topics with the wider scientific community through our digital open innovation portal, opnMe.com, and seek their input on and proposals for critical challenges.
With our very first call, from the field of biological therapeutics, we invite you to address the following question:
“Leveraging novel technological approaches in downstream processing of biologicals, how would you propose to reduce water and/or energy consumption in future bioprocesses?”
Submissions are now open until Feb 15, 2023. The winner will receive a $80,000 grant for the implementation of an idea that can be completed within 12 months and has the potential for tangible impact. We are looking forward to receiving your idea!
IU Sustainability aims to minimize the environmental footprint of our future medicines by focusing on sustainable science and innovation, based on the principles of eco-design and green chemistry, starting from the synthesis of the biological or small molecule drug substance all the way to the packaged medicinal product and device. By doing so, we are contributing to the ambition of Boehringer Ingelheim’s Sustainable Development for Generations framework to embed sustainability into the core of our business.
Through opnMe.com, we have successfully interacted with scientists from over 65 countries, who either accessed our well-characterized probe molecules for preclinical research or collaborated with us on research projects with an impact for patients in need. opnMe.com originated from Boehringer Ingelheim’s Discovery Research group with the aim to interact with researchers for the advancement of early preclinical projects in healthcare. opnMe has now over 4,300 registered users, and 1,400 collaboration proposals have been received since its inception in Nov 2017. Now, in the portal’s fifth year, we are launching our first IU Sustainability challenge question to find innovative approaches that can contribute to minimizing our environmental impact while creating life-changing solutions for our patients.